Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 653
- Registration Number
- NCT03125902
- Locations
- 🇺🇸
Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States
🇨🇿Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia
🇸🇰Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A, Bratislava, Slovakia
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 806
- Registration Number
- NCT03114657
- Locations
- 🇺🇸
Texas Neurology PA, Dallas, Texas, United States
🇮🇹Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy
🇪🇸Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain
Quality of Life Study in Participants With IPF Under Pirfenidone Treatment
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT03115619
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology, Athens, Greece
🇬🇷University General Hospital of Athens "Attikon", B' University Pulmonary Clinic, Chaidari, Greece
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT03112213
- Locations
- 🇩🇪
Praxis Prof. Dr.med. Herbert Kellner, München, Germany
🇩🇪Rheumazentrum Kupka, Altenburg, Germany
🇩🇪Praxis für Rheumatologie., Amberg, Germany
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03101280
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸La Paz University Hospital, Madrid, Spain
🇫🇷Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale, Pierre Benite, France
An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Other: No Intervention
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT03099200
- Locations
- 🇬🇧
Nevill Hall Hospital, Abergavenny, United Kingdom
🇬🇧Royal Devon & Exeter Hospital; Oncology Centre, Exeter, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, United Kingdom
Compare Bioavailability of RO7239361 After Subcutaneous Injection
- Conditions
- Healthy
- Interventions
- Drug: RO7239361
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT03100630
- Locations
- 🇺🇸
WCCT Global, Inc., Cypress, California, United States
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: RO7046015Drug: Placebo
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT03100149
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 253
- Registration Number
- NCT03099187
- Locations
- 🇦🇺
John Hunter Hospital; Respiratory Department; Respiratory Department, New Lambton Heights, New South Wales, Australia
🇦🇺Lung Research Queensland, Nundah, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine, Woolloongabba, Queensland, Australia
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
- Conditions
- Carcinoma, Non-Small-Cell LungCarcinoma, Small Cell
- Interventions
- Diagnostic Test: PD-L1 Immunocytochemistry (ICC)Diagnostic Test: PD-L1 Immunohistochemistry (IHC)
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 184
- Registration Number
- NCT03092739
- Locations
- 🇨🇭
Universitätsspital Basel; Pathologie, Basel, Switzerland
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇪🇸Hospital Universitario La Paz; Servicio de Anatomia Patologica, Madrid, Spain